Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.38 SEK | -0.74% | +1.85% | +7.82% |
May. 06 | Humana Names Successor to Outgoing President/CEO | MT |
May. 06 | Humana AB Announces CEO Changes | CI |
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company shows low valuation levels, with an enterprise value at 0.61 times its sales.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.82% | 135M | B | ||
+25.43% | 1.41B | B | ||
+0.84% | 1.43B | - | C+ | |
-28.22% | 1.37B | - | ||
+23.24% | 756M | - | B | |
-7.27% | 448M | B- | ||
+235.30% | 425M | - | D+ | |
-5.33% | 331M | - | - | |
+45.86% | 94.87M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HUM Stock
- Ratings Humana AB